Harrow offers asymmetric upside if its branded ophthalmology platform scales fast enough to outrun gross-to-net volatility and a leveraged balance sheet.
Overview
Harrow is a vertically integrated U.S. ophthalmic pharmaceutical platform transitioning from legacy compounding into higher-value branded therapeutics. Its core assets—Vevye, Iheezo, Triesence, Byooviz, and Opuviz—target dry eye, surgical anesthesia, inflammation, and retinal disease. The company serves ophthalmologists, optometrists, surgery centers, retina clinics, and hospital pharmacies through a lean direct-sales model. Its differentiated edge is a hybrid branded-compounding ecosystem that reduces payer friction, preserves clinic workflows, and gives physicians both premium FDA-approved products and lower-cost customized alternatives.